1	State of Arkansas 95th General Assembly	As Engrossed: H1/30/25 ${ m A}~{ m Bill}$	
2 3	Regular Session, 2025		HOUSE BILL 1055
3 4	Regular Session, 2025		HOUSE BILL 1055
4 5	By: Representatives J. May	/berry, Rye, Breaux, Springer	
6	By: Senators C. Penzo, F. I		
7			
8		For An Act To Be Entitled	
9	AN ACT TO ESTABLISH COVERAGE DIAGNOSIS AND TREATMENT		
10	TO SLOW	THE PROGRESSION OF ALZHEIMER'S DISEASE OF	ł
11	OTHER DE	MENTIA-RELATED DISEASE UNDER THE STATE AN	1D
12	PUBLIC SCHOOL LIFE AND HEALTH INSURANCE PROGRAM; AND		
13	FOR OTHE	R PURPOSES.	
14			
15			
16		Subtitle	
17	то	ESTABLISH COVERAGE DIAGNOSIS AND	
18	TRI	EATMENT TO SLOW THE PROGRESSION OF	
19	ALZ	ZHEIMER'S DISEASE OR OTHER DEMENTIA-	
20	REI	LATED DISEASE UNDER THE STATE AND	
21	PUI	BLIC SCHOOL LIFE AND HEALTH INSURANCE	
22	PRO	DGRAM.	
23			
24	BE IT ENACTED BY THE	GENERAL ASSEMBLY OF THE STATE OF ARKANSA	\S:
25			
26	SECTION 1. Ar	kansas Code Title 21, Chapter 5, Subchapt	er 4, is amended
27	to add an additional	section to read as follows:	
28	<u>21-5-425. Cov</u>	erage for diagnosis and treatment of Alzh	<u>neimer's disease</u>
29	<u>or other dementia-re</u>	lated disease — Legislative findings and	<u>intent - Rules.</u>
30	<u>(a) The Gener</u>	al Assembly finds that:	
31	<u>(1) Alz</u>	heimer's disease is the seventh leading o	ause of death in
32	<u>Arkansas according t</u>	to the Centers for Disease Control and Pre	evention;
33	<u>(2) The</u>	cost of managing the complications of la	<u>ite-stage</u>
34	<u>Alzheimer's disease,</u>	largely due to delayed diagnosis and acc	ess to
35	treatment, outweighs	the cost of expeditious and effective tr	ceatment;
36	(3) The	diagnosis and treatment of Alzheimer's d	lisease or other



As Engrossed: H1/30/25

HB1055

1	dementia-related disease should be a clinical decision made by a physician		
2	based on evidence-based guidelines; and		
3	(4) The United States Food and Drug Administration has granted		
4	approval for treatments of patients in the early stages of Alzheimer's		
5	disease.		
6	(b) It is the intent of the General Assembly to provide coverage for		
7	the diagnosis and treatment of Alzheimer's disease or other dementia-related		
8	disease.		
9	(c) Each state employee's and public school employee's health benefit		
10	plan under the State and Public School Life and Health Insurance Program that		
11	is offered, issued, or renewed on or after January 1, 2026, shall offer		
12	coverage for the diagnosis and treatment of Alzheimer's disease or other		
13	dementia-related disease as determined by a physician licensed to practice		
14	medicine in this state and according to the standards or guidance established		
15	by the United States Food and Drug Administration.		
16	(d) The coverage and treatment of Alzheimer's disease or other		
17	dementia-related disease offered under subsection (c) of this section shall:		
18	(1) Be a treatment or medication that has been approved by the		
19	United States Food and Drug Administration to treat or slow the progression		
20	of Alzheimer's disease or other dementia-related disease;		
21	(2) Include without limitation:		
22	(A) Any diagnostic testing that is necessary for a		
23	physician to determine the appropriate use of treatments and medications		
24	under subdivision (d)(l) of this section; and		
25	(B) All treatments or medications prescribed to slow the		
26	progression of Alzheimer's disease or other dementia-related disease; and		
27	(3) Not be subject to step therapy protocols.		
28	(e) The State Board of Finance may promulgate rules to implement this		
29	section.		
30			
31	/s/J. Mayberry		
32			
33			
34			
35			
36			

2